Operating Income (Loss) of CITIUS ONCOLOGY, INC. from 31 Dec 2022 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- The net result for the period of deducting operating expenses from operating revenues.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2022 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Operating Income (Loss) for the quarter ending 31 Dec 2025 was $5,252,276, a 18% increase year-over-year.
- CITIUS ONCOLOGY, INC. annual Operating Income (Loss) for 2025 was $23,522,750, a 14% decline from 2024.
- CITIUS ONCOLOGY, INC. annual Operating Income (Loss) for 2024 was $20,572,747, a 1931% decline from 2023.
- CITIUS ONCOLOGY, INC. annual Operating Income (Loss) for 2023 was $1,013,070, a 633% decline from 2022.
- Source SEC data
- View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)
CITIUS ONCOLOGY, INC. Quarterly Operating Income (Loss) (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $5,252,276 | +$1,142,689 | +18% | 01 Oct 2025 | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 | |
| Q2 2025 | $4,944,961 | -$316,111 | -6.8% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 | |
| Q4 2024 | $26,723,573 | $6,394,965 | -$6,150,826 | -2519% | 01 Oct 2024 | 31 Dec 2024 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2024 | $20,572,747 | $15,431,329 | -$15,009,874 | -3561% | 01 Jul 2024 | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q2 2024 | $5,562,873 | $4,628,850 | -$4,429,296 | -2220% | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q3 |
| Q1 2024 | $1,133,577 | $268,429 | -$120,507 | -81% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 20 May 2024 | 2024 | Q1 |
| Q4 2023 | $1,013,070 | $244,139 | 01 Oct 2023 | 31 Dec 2023 | 10-K | 16 Apr 2024 | 2023 | FY | ||
| Q3 2023 | $421,455 | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 20 Nov 2023 | 2023 | Q3 | |||
| Q2 2023 | $199,554 | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 | |||
| Q1 2023 | $147,922 | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 20 May 2024 | 2024 | Q1 |
CITIUS ONCOLOGY, INC. Annual Operating Income (Loss) (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $23,522,750 | -$2,950,003 | -14% | 01 Oct 2024 | 30 Sep 2025 | 10-K | 23 Dec 2025 | 2025 | FY |
| 2024 | $20,572,747 | -$19,559,677 | -1931% | 01 Oct 2023 | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| 2023 | $1,013,070 | -$874,955 | -633% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 16 Apr 2024 | 2023 | FY |
| 2022 | $138,115 | 01 Jan 2022 | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.